UDC 618.19-006.55-06:616.12-008.3331.1]-085:615.28

Introduction. Elevated blood pressure (BP) during treatment with anthracyclines, which include doxorubicin and epirubicin, may be a factor in polychemotherapy (PCT)-related cardiotoxicity, which necessitates monitoring and adjustment of BP in these patients. The aim of the study. The principal objective of this research was to investigate fluctuations in blood pressure levels during multi-agent chemotherapy incorporating anthracyclines, cyclophosphamide, and paclitaxel in individuals diagnosed with mammary carcinoma.Materials and methods. The investigation enrolled 86 female patients diagnosed with breast cancer (T2-4, N0-1, M0). These individuals were subsequently randomized and underwent a neoadjuvant PCT. The treatment involved the administration of anthracyclines in conjunction with cyclophosphamide, delivered 3-weekly for 4 cycles. Upon the conclusion of this twelve-week anthracycline-based therapeutic course, participants proceeded to receive weekly infusions of paclitaxel.Results. Blood pressure monitoring during PCT showed that the subjects had a significant increase in mean systolic blood pressure after infusions in the doxorubicin group (from 123.1 + 1.8 to132.3 + 2.4 mmHg,p < 0.001) and the epirubicin group (from122.7 + 2.7 to135.6 + 2.3 mmHg,p = 0.002). Diastolic blood pressure in the doxo-rubicin group increased by an average of 4.4 mm Hg (95.0 % CI: 0.5-15.1 mm Hg) and by 3.8 mm Hg (95.0 % CI: 1.8-12.4 mm Hg) in the epirubicin group. Paclitaxel treatment procedures did not lead to a significant increase in blood pressure in patients in either group. Non-pharmacological measures did not significantly affect changes in blood pressure during PCT with anthracyclines in combination with cyclophosphamide and paclitaxel in the majority of patients. Conclusions. The administration of combination chemotherapy, specifically involving anthracyclines and cyclophosphamide, is associated with a substantial post-procedural elevation in mean blood pressure. Paclitaxel infusions were not accompanied by significant changes in mean blood pressure during procedures.

UDC 616.5–002.525.2–031.81–06:616.12–037

Introduction. Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease frequently associated with cardiac lesion.The aim of the study. To elucidate the prognostic power of clinical predictors of syntropical cardiac lesions in patients with systemic lupus erythematosus.Materials and methods. The study included 118 patients with SLE and cardiac manifestations, most of whom were young women. Patients were stratified according to the presence of SLE-associated cardiac lesion. Data were analyzed using Excel; statistical significance was defined as p < 0.050. An association was considered confirmed if the association coefficient is ≥0.50 or the contingency coefficient is ≥0.30. Results. The study identified the predictive power of clinical indicators and determined that the most informative constellation for detecting mitral valve insufficiency was "joint pain + new skin rash + accentuated second heart sound over the aortic area" with an absolute risk (AR) 93.75 %, for mitral leaflet thickening the optimal constellation was "dyspnea + sensation of irregular heartbeats" (AR 69.23 %), for pericardial effusion it was "joint pain + diminished heart soundsv (AR 33.33 %), for myocarditis the best constellation was "palpitations + systolic murmur at the cardiac apex" (AR 55.17 %). No predictive constellation was found for endocarditis.Conclusions. For each syntropical cardiac lesion in patients with systemic lupus erythematosus, the clinical predictors or their constellations that have optimal prognostic strength, have been elucidated.